Graham G. Walmsley's Form 4 filing
Olema Pharmaceuticals, Inc. (OLMA) · filed Dec 17, 2024
- Accession no.
- 0000935836-24-000763
- Filed
- Dec 17, 2024
- Trade date
- Dec 17, 2024
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $4.73M. Open-market sales total $4.73M. It was filed on the trade date.
This filing was later replaced by the amendment 0000935836-24-000764 (Dec 18, 2024). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Graham G. WalmsleyCIK 0001777517 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 17, 2024 | Common Stock | SSaleDisposed | −700,761 | $6.75 | −$4,730,136.75 | 0 | Indirect | |
| Dec 17, 2024 | Common Stock | PPurchaseDisposed | −700,761 | $6.75 | −$4,730,136.75 | 1,408,875 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.